News
Discover how tirzepatide benefits heart failure in obesity, and see why those with higher BMI may gain even more benefits.
Eli Lilly's Mounjaro matched Trulicity in heart outcomes and showed added benefits on A1C, weight, kidney function, and ...
Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...
Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...
Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...
While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase III cardiovascular outcomes trial, analysts had hoped for statistical ...
Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...
Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...
7d
News-Medical.Net on MSNChinese study shows lasting weight loss after tirzepatide treatmentObesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, ...
Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.
Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results